CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Market News Lilly to adjust organization and leadership structure
News
5 Jan 2017

Lilly to adjust organization and leadership structure

Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business.

Eli Lilly is to make a series of changes to its organization and leadership structure to better align them with the company's growth opportunities.

Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said: "Lilly begins 2017 with a clear view of its opportunities for growth in the years ahead. The adjustments we are announcing today to pharmaceutical therapeutic and geographic business areas are designed to maximize the potential of our late-stage pipeline and newly launched medicines, while improving productivity."

The company announced the following changes:

  • Christi Shaw has been hired to lead the company's Bio-Medicines business beginning 3 April. Shaw will succeed Ricks, who became Lilly's president and CEO on 1 January, as senior vice president and president of Lilly Bio-Medicines. Shaw, who started her career at Lilly in 1989, has more than 25 years of pharmaceutical and medical device experience.

  • Beginning on 1 February, Lilly's Diabetes, Oncology and Bio-Medicines human pharmaceutical therapeutic business areas will assume commercial responsibility for their products in China — in addition to the US, Japanese and Canadian markets in which they already operate.

  • Lilly Diabetes will host the company's human pharmaceutical commercial operations in the US, China, Japan and Canada. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes, will assume additional responsibilities as president of Lilly USA.

  • Lilly's current Emerging Markets business will combine with Europe to form Lilly International, which will have commercial responsibility for the company's human pharmaceutical products in these markets. Alfonso (Chito) Zulueta, who has led the Emerging Markets business for the last 3 years, will be senior vice president of Lilly and president of Lilly International.

  • Sue Mahony will continue as senior vice president of Lilly and president of Lilly Oncology.

  • Alex Azar, president of Lilly USA, has decided to leave Lilly to pursue other career opportunities.

    • These organizational changes are expected to increase productivity and simplify Lilly's global commercial organization. These changes will also result in a reduction in leadership positions. In December, the company announced reductions to its US field force in anticipation of patent expirations for key products later this year and in response to clinical trial results on solanezumab.

    "With new medicines recently launched — and potential new medicines in development for cancer, diabetes, autoimmune diseases, neurodegeneration, and pain — Lilly is in the early stages of a new growth period," said Ricks. "Now is the time to make sure that our organization is set up to make the most of these opportunities. With clear priorities and the right structure, achieving growth while improving our productivity will go hand-in-hand."

    "I'm confident that these changes will help to increase the flow of innovation from our pipeline and maximize opportunities in priority therapeutic and geographic areas," Ricks said.

    Related tags
    Market

    Related News